CD86 and neoplasm: In fact, an increment of CD86+ M1 macrophages in C51 FL Rnaset2-injected mice was observed in comparison to both C51 E and C51 P control mice at day 14 post-tumor injection, coupled to a more pronounced decrease of CD206+ M2 macrophages that remained unchanged until day 20.